TABLE 2.
Characteristics of laboratory-confirmed SARS-CoV-2 infections among Chicagoans after receipt of tixagevimab-cilgavimab (n = 75).
| n (%) | |
|---|---|
| Outcomes | |
| Hospitalization due to COVID-19 | 12 (16.0) |
| Deceased due to COVID-19 | 1 (1.5) |
| Tixagevimab-cilgavimab exposure at infection a | |
| Partial dose within 6 months (150 mg each) | 9 (12.0) |
| Full dose within 6 months (300 mg each) | 48 (64.0) |
| More than 6 months from treatment | 19 (25.3) |
| Time from dosing to infection, days (median, IQRb) | |
| Partial dose within 6 months (150 mg each) | 134 (113–175) |
| Full dose within 6 months (300 mg each) | 105 (35–141) |
| More than 6 months from treatment | 107 (61–151) |
| Overall | 138 (89–194) |
| Indications for treatment c | |
| B-cell depleting agent specified | 10 (13.3) |
| Hematologic malignancy | 8 (10.6) |
| Solid organ transplant | 7 (9.3) |
| Stem cell transplant | 7 (9.3) |
| Multiple sclerosis | 2 (2.7) |
| T-cell depleting agent specified | 2 (2.7) |
| Unspecified condition requiring immunosuppression | 7 (9.3) |
| Unknown | 48 (64.0) |
a
The Food and Drug Administration recommended tixagevimab-cilgavimab treatment at 6-month intervals.
b
IQR: Interquartile range.
c
Indications reported for 27/75 (36%) of patients, some with multiple indications reported.